BMO Capital Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $40

BMO Capital analyst Kostas Biliouris maintains $4D Molecular Therapeutics(FDMT.US)$ with a buy rating, and maintains the target price at $40.According to TipRanks data, the analyst has a success

Moomoo News06:31 ET · Ratings

Why Domino's Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Shares of Domino's Pizza, Inc. (NYSE:DPZ) fell sharply during Thursday's session after the company reported mixed quarterly results.The company reported second-quarter FY24 sales growth of 7.1% year-

Benzinga13:19 ET

Peeling Back The Layers: Exploring 4D Molecular Therapeutics Through Analyst Insights

In the preceding three months, 5 analysts have released ratings for 4D Molecular Therapeutics (NASDAQ:FDMT), presenting a wide array of perspectives from bullish to bearish.Summarizing their recent

BenzingaJul 18 10:00 ET

4D Molecular Therapeutics Is Maintained at Outperform by BMO Capital

4D Molecular Therapeutics Is Maintained at Outperform by BMO

Dow JonesJul 18 09:32 ET

A Quick Look at Today's Ratings for 4D Molecular Therapeutics(FDMT.US), With a Forecast Between $38 to $82

On Jul 18, major Wall Street analysts update their ratings for $4D Molecular Therapeutics(FDMT.US)$, with price targets ranging from $38 to $82.BofA Securities analyst Tazeen Ahmad maintains with a

Moomoo NewsJul 18 09:00 ET · Ratings

Express News | 4D Molecular Therapeutics Inc : BMO Cuts Target Price to $40 From $63

ReutersJul 18 07:00 ET